GlaxoSmithKline is trading 4.9% up at $48.80 in after-hours trading, with no reliable report explaining the rebound. - The regular-session close was $46.52 on October 5, 2026. - Earlier that day, analysts raised concerns about potential billions of dollars in Zantac-related liabilities ahead of upcoming U.S. trials. GlaxoSmithKline said the litigation was inconsistent with scientific consensus, citing FDA and EMA conclusions that there is no evidence of a causal association between ranitidine and cancer. - The available report linked those comments to a decline, not the after-hours rise.